Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Shock. 2020 Apr;53(4):452-459. doi: 10.1097/SHK.0000000000001390.
The use of norepinephrine may be associated with better outcomes in some patients with shock. We sought to determine whether norepinephrine was associated with lower mortality in unselected cardiac intensive care unit (CICU) patients compared with other vasopressors, and whether patterns of vasopressor and inotrope usage in the CICU have changed over time.
We retrospectively evaluated consecutive adult patients admitted to a tertiary care hospital CICU from January 1, 2007 to December 31, 2015. Vasoactive drug doses were quantified using the peak Vasoactive-Inotropic Score (VIS). Temporal trends were assessed using the Cochran-Armitage trends test and multivariable logistic regression was used to determine predictors of hospital mortality.
We included 10,004 patients with a mean age of 67 ± 15 years; vasoactive drugs were used in 2,468 (24.7%) patients. Use of norepinephrine increased over time, whereas dopamine utilization decreased (P < 0.001 for trends). After adjustment for illness severity and other variables, the peak VIS was a predictor of hospital mortality across the entire population (unit odds ratio [OR] 1.013, 95% confidence interval [CI], 1.009-1.017, P < 0.001) and among patients receiving vasoactive drugs (OR 1.018, 95% CI, 1.013-1.022, P < 0.001). Among patients receiving vasoactive drugs, norepinephrine was associated with a lower risk of hospital mortality (OR 0.66, 95% CI, 0.49-0.90, P = 0.008) after adjustment for illness severity and peak VIS.
Vasoactive drug use in CICU patients has a dose-dependent association with short-term mortality. Use of norepinephrine in CICU patients is associated with decreased odds of death when compared with other vasoactive drugs.
去甲肾上腺素的使用可能与一些休克患者的更好结果相关。我们旨在确定去甲肾上腺素与其他血管加压药相比,在未选择的心脏重症监护病房(CICU)患者中是否与更低的死亡率相关,以及 CICU 中血管加压药和正性肌力药的使用模式是否随时间而变化。
我们回顾性评估了 2007 年 1 月 1 日至 2015 年 12 月 31 日期间连续入住一家三级护理医院 CICU 的成年患者。使用峰值血管活性-正性肌力评分(VIS)量化血管活性药物剂量。使用 Cochran-Armitage 趋势检验评估时间趋势,使用多变量逻辑回归确定医院死亡率的预测因素。
我们纳入了 10004 例平均年龄为 67±15 岁的患者;2468 例(24.7%)患者使用了血管活性药物。去甲肾上腺素的使用随着时间的推移而增加,而多巴胺的使用率则下降(趋势 P<0.001)。在校正疾病严重程度和其他变量后,峰值 VIS 是整个人群(单位比值比 [OR] 1.013,95%置信区间 [CI],1.009-1.017,P<0.001)和接受血管活性药物治疗的患者(OR 1.018,95%CI,1.013-1.022,P<0.001)医院死亡率的预测因素。在接受血管活性药物治疗的患者中,在校正疾病严重程度和峰值 VIS 后,去甲肾上腺素与较低的医院死亡率相关(OR 0.66,95%CI,0.49-0.90,P=0.008)。
CICU 患者血管活性药物的使用与短期死亡率呈剂量依赖性相关。与其他血管活性药物相比,CICU 患者使用去甲肾上腺素与死亡几率降低相关。